Raphael Pharmaceutical (RAPH) Total Current Liabilities (2020 - 2026)

Raphael Pharmaceutical has disclosed Total Current Liabilities across 7 years of filings, most recently posting $1.9 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 75.51% year-over-year to $1.9 million; the TTM figure through Jun 2026 stood at $1.9 million (up 75.51% YoY), while the FY2025 annual figure was $1.5 million, up 93.24% from the prior year.
• Total Current Liabilities came in at $1.9 million for Q2 2026 at Raphael Pharmaceutical, up from $1.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.9 million in Q2 2026 to a low of $77000.0 in Q1 2022.
• Average Total Current Liabilities over 5 years is $610470.6, with a median of $456000.0 recorded in 2024.
• Year-over-year, Total Current Liabilities tumbled 41.85% in 2023 and jumped 482.58% in 2024.
• Over 5 years, Total Current Liabilities stood at $227000.0 in 2022, then slumped by 41.85% to $132000.0 in 2023, then jumped by 482.58% to $769000.0 in 2024, then jumped by 93.24% to $1.5 million in 2025, then increased by 27.32% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $1.9 million in Q2 2026, $1.5 million in Q4 2025, and $1.3 million in Q3 2025.